Advertisement

Abstract

Methotrexate (MTX) is a folate analogue originally developed in the 1940s as a highly selective inhibitor of dihydrofolate reductase (DHFR). Its use in the reduction of rheumatoid arthritis (RA) synovitis was first reported in a 1951 paper on six RA patients by Gubner and Ginsburg and explained as a cytotoxic effect on proliferating lymphocytes. Subsequently its efficacy in RA was proven in a series of papers in the mid 1980s and it is now the mainstay of RA therapy, both alone and in combination, as recommended in the guidelines of the American College of Rheumatology 2002 [1].

Keywords

Rheumatoid Arthritis Triple Therapy Health Assessment Questionnaire Radiological Progression Health Assessment Questionnaire Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46: 328–346CrossRefGoogle Scholar
  2. 2.
    Jobanputra P, Wilson J, Douglas K, Burls A (2004) A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis. Rheumatology 43: 206–210CrossRefPubMedGoogle Scholar
  3. 3.
    Grim J, Chládek J, Martínková J (2003) Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 42: 139–151CrossRefPubMedGoogle Scholar
  4. 4.
    Furst DE (1997) The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 36: 1196–1204CrossRefPubMedGoogle Scholar
  5. 5.
    Kremer JM, Petrillo GF, Hamilton RA (1995) Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 22: 38–40PubMedGoogle Scholar
  6. 6.
    Cronstein BN (1997) The mechanism of action of methotrexate. Rheum Dis Clin North Am 23: 739–755CrossRefPubMedGoogle Scholar
  7. 7.
    Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE (1991) Aspirin alters methotrexate disposition in rheumatoid arthritis. Arthritis Rheum 34: 1514–1520CrossRefPubMedGoogle Scholar
  8. 8.
    Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Hussain MA (1998) The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharmaceutics & Drug Disposition 3: 163–167CrossRefGoogle Scholar
  9. 9.
    Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clinical Pharmacokinetics 30: 194–210CrossRefPubMedGoogle Scholar
  10. 10.
    Cutolo M, Sulli A, Pizzorni C, Seriolo B (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60: 729–735CrossRefPubMedGoogle Scholar
  11. 11.
    Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, Villagio B (2000) Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from rheumatoid arthritis patients. J Rheumatol 27: 2551–2557PubMedGoogle Scholar
  12. 12.
    Weinblatt ME, Maier AL, Fraser PA, Coblyn JS (1998) Longterm prospective study of methotrexate in rheumatoid arthritis: conclusions after 132 months of therapy. J Rheumatol 25: 238–242PubMedGoogle Scholar
  13. 13.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2004) Bioavail-ability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31: 645–648PubMedGoogle Scholar
  14. 14.
    Tugwell P, Bennett K, Gent M (1987) Methotrexate in rheumatoid arthritis. Ann Intern Med 107: 358–366PubMedGoogle Scholar
  15. 15.
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Archives Int Med 159: 2542–2550CrossRefGoogle Scholar
  16. 16.
    Ortendahl M, Holmes T, Schettler JD, Fries JF (2002) The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 29: 2084–2091PubMedGoogle Scholar
  17. 17.
    Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, Van den Bosch F, Nordström D, Bjørneboe O, Dahl R et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39: 655–665CrossRefPubMedGoogle Scholar
  18. 18.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J et al (2001) Two-year, blinded, randomised, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 44: 1984–1992CrossRefPubMedGoogle Scholar
  19. 19.
    Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, Meusser S, Paimela L, Rau R, Zeidler H et al (1999) Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58: 220–225CrossRefPubMedGoogle Scholar
  20. 20.
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343: 1586–1593CrossRefPubMedGoogle Scholar
  21. 21.
    Sharp JT (1996) Scoring radiographic abnormalities in rheumatoid arthritis. Radiol Clin North Am 34: 233–241PubMedGoogle Scholar
  22. 22.
    van der Heij de DM, van Leeuwen MA, van Riel PLCM, Koster AM, van’t Hof MA, van Rijswijk MH, van de Putte LB (1992) Biannual radiographic assessments of hands and feet in the three year prospective follow up of patients with early rheumatoid arthritis. Arthritis Rheum 35: 26–34CrossRefGoogle Scholar
  23. 23.
    Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, and the Leflunomide Rheumatoid Arthritis Investigators Group (2000) Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 43: 495–505CrossRefPubMedGoogle Scholar
  24. 24.
    Wolfe F, Sharp JT (1998) Radiographic outcome of recent-onset rheumatoid arthritis. Arthritis Rheum 41: 1571–1582CrossRefPubMedGoogle Scholar
  25. 25.
    Alarcón GS, Lopez-Mendez A, Walter J, Boerbooms AM, Russell AS, Furst DE, Rau R, Drosos AA, Bartolucci AA (1992) Radiographic evidence of disease progression in methotrexate drug-treated RA. J Rheumatol 19: 1868–1873PubMedGoogle Scholar
  26. 26.
    Landewé RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MAFJ, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BAC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 46: 347–356CrossRefPubMedGoogle Scholar
  27. 27.
    Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42: 1854–1860CrossRefPubMedGoogle Scholar
  28. 28.
    Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594–1602CrossRefPubMedGoogle Scholar
  29. 29.
    Guzman J, Maetzel A, Peloso P, Yeung M, Bombardier C (1996) Disability scores in DMARD trials: what is a clinically important change? Arthritis Rheum 39: S208Google Scholar
  30. 30.
    Kirwan JR (2001) Links between radiological change, disability and pathology in rheumatoid arthritis. J Rheumatol 28: 881–886PubMedGoogle Scholar
  31. 31.
    Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E et al (1994) Methotrexate in rheumatoid arthritis: A 5 year prospective multicenter study. Arthritis Rheum 37: 1492–1498CrossRefPubMedGoogle Scholar
  32. 32.
    Kremer JM (1996) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow up after a mean of 13.3 years. Arthritis Rheum 39: 984–985CrossRefGoogle Scholar
  33. 33.
    Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis. Arthritis Rheum 43: 22–29CrossRefPubMedGoogle Scholar
  34. 34.
    Ranganathan P, Eisen S, Yokoyama WM, McLeod HL (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62: 4–9CrossRefPubMedGoogle Scholar
  35. 35.
    Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CS, Li S, Liu H et al (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231–234CrossRefPubMedGoogle Scholar
  36. 36.
    Haagsma CJ, Blom HJ, van Riel PL, van’t Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58: 79–84CrossRefPubMedGoogle Scholar
  37. 37.
    van Ede AE, Laan RF, Blom HJ, Huizinga TWJ, Haagsma CJ, Giesendorf BAJ, de Boo TM, van de Putte LBA (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44: 2525–2530CrossRefPubMedGoogle Scholar
  38. 38.
    Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12: 183–190CrossRefPubMedGoogle Scholar
  39. 39.
    O’Dell JR (1998) Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. Rheum Dis Clin North Am 24: 465–477CrossRefPubMedGoogle Scholar
  40. 40.
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. NEJM 333: 137–141CrossRefPubMedGoogle Scholar
  41. 41.
    Fox RI, Morgan SL, Smith HT, Robbins BA, Choc MG, Baggott JE (2003) Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology 42: 989–994CrossRefPubMedGoogle Scholar
  42. 42.
    Fries JF, Singh G, Lenert L, Furst DE (1990) Aspririn, hydroxychoroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 33: 1611–1619CrossRefPubMedGoogle Scholar
  43. 43.
    Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C (1994) Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum 37: 830–833CrossRefPubMedGoogle Scholar
  44. 44.
    Carmichael SJ, Beal J, Day RO, Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29: 2077–2083PubMedGoogle Scholar
  45. 45.
    Kremer JM, Genovese MC, Cannon, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Key-stone E, Weisman MH, Bensen WE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomised comparison of efficacy, safety and tolerability compared to methotrexate alone. Ann Intern Med 137: 726–733PubMedGoogle Scholar
  46. 46.
    O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334: 1287–1291CrossRefPubMedGoogle Scholar
  47. 47.
    O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J et al (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate, sulfasalazine, or a combination of the three medications. Arthritis Rheum 46: 1164–1170CrossRefPubMedGoogle Scholar
  48. 48.
    Pincus T, Marcum SB, Callahan LF (1992) Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone. J Rheumatol 19: 1885–1894PubMedGoogle Scholar
  49. 49.
    Aletaha D, Stamm T, Kaprai T, Eberl G, Grisar J, Machold KP, Smolen JS (2003) Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 62: 944–951CrossRefPubMedGoogle Scholar
  50. 50.
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS (1990) The effect of folic acid supplementation on the toxicity of low dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 9–18CrossRefPubMedGoogle Scholar
  51. 51.
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis; a double-blind placebo-controlled trial. Ann Intern Med 121: 833–841PubMedGoogle Scholar
  52. 52.
    Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P (2003) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley &c Sons, ChichesterGoogle Scholar
  53. 53.
    van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomised, double-blind, placebo-controlled study. Arthritis Rheum 44: 1515–1524CrossRefPubMedGoogle Scholar
  54. 54.
    Whittle SL, Hughes RA (2004) Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 43: 267–271CrossRefPubMedGoogle Scholar
  55. 55.
    Fathi NH, Mitros F, Hoffman J, Straniero N, Labreque D, Koehnke R, Furst DE (2002) Longitudinal measurement of methotrexate concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 29: 2092–2098PubMedGoogle Scholar
  56. 56.
    Merrill JT, Cronstein BN, Shen C, Goodman S, Paget S, Mitnick H, Greisman S, Bauer B, Diakolios C, Fisher R et al (1996) Reversal of new but not old rheumatoid nodules by colchicine: evidence from an in vitro model and case reports of 14 patients. Arthritis Rheum 39: S240Google Scholar
  57. 57.
    Abraham Z, Rozenbaum M, Rosner I (1999) Colchicine therapy for low dose methotrexate induced accelerated nodulosis in a rheumatoid arthritis patient. J Dermatol 26:691–694PubMedGoogle Scholar
  58. 58.
    Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross WL (1996) Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 15: 277–282CrossRefPubMedGoogle Scholar
  59. 59.
    Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, St Clair EW, Sundy JS, Alexander RW, Smith GJ et al (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicentre, case-control study. Methotrexate study group. Ann Intern Med 127: 356–364PubMedGoogle Scholar
  60. 60.
    Saravanan V, Kelly CA (2004) Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 43: 143–147CrossRefPubMedGoogle Scholar
  61. 61.
    Beauparalant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29: 148–158CrossRefGoogle Scholar
  62. 62.
    Barnhart K, Coutifaris C, Esposito M (2001) The pharmacology of methotrexate. Expert Opin Pharmaco 2: 409–417CrossRefGoogle Scholar
  63. 63.
    Morris LF, Harrod MJ, Menter A, Silverman AK (1993) Methotrexate and reproduction in men: Case report and recommendations. J Am Acad Dermatol 29: 913–916CrossRefPubMedGoogle Scholar
  64. 64.
    Prashker MJ, Meenan RF (1995) The total cost of drug therapy for rheumatoid arthritis. Arthritis Rheum 38: 318–325CrossRefPubMedGoogle Scholar
  65. 65.
    Kremer JM, Alarcón GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37: 316–328CrossRefPubMedGoogle Scholar
  66. 66.
    Choi HK, Seeger JD, Kuntz KM (2002) A cost effectiveness analysis of treatment options for methotrexate naïve rheumatoid arthritis. J Rheumatol 291156–1165PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Kevin Pile
    • 1
  1. 1.Institute of MedicineJames Cook University, Townsville HospitalTownsvilleAustralia

Personalised recommendations